Department of Surgery, City of Hope National Medical Center, Duarte, California.
Department of Surgery, MD Anderson Cancer Center, Howard University, Washington, DC, Houston Texas.
J Surg Res. 2019 Apr;236:216-223. doi: 10.1016/j.jss.2018.11.040. Epub 2018 Dec 20.
Investigating methods to assess the quality of cancer surgery and then benchmarking hospitals on these quality indicators can lead to improvements in cancer care in the United States. We sought to determine the utility of lymph node count as a quality metric.
We performed a retrospective analysis of the California Cancer Registry database (2004-2011) merged with Office of Statewide Health Planning and Development inpatient database. Patients with locally advanced rectal adenocarcinoma who underwent neoadjuvant therapy and resection were included. Hospital quality score was defined as the proportion of patients at a particular hospital that had adequate examination with at least nine lymph nodes. High-quality score hospitals were those that retrieved nine or more nodes among ≥25% of operations. A multivariate Cox proportional hazards (standard and shared frailty) model was used to determine differences in overall survival adjusting for age, hospital volume, race, sex, insurance, comorbidity, T-stage, response to neoadjuvant therapy, adjuvant chemotherapy, and teaching hospital status as covariates.
A total of 2704 patients were treated at 228 hospitals (low-scoring hospital = 85 and high-scoring hospital = 143). Patient- and disease-specific characteristics were similar between the groups. Socioeconomic status and hospital characteristics were strongly associated with score status. High-scoring hospitals had higher sphincter preservation (P = 0.004), lower complications (P = 0.021), and a trend toward lower mortality (P = 0.079). Care at high-scoring hospitals independently predicted overall survival (hazard ratio: 0.74; 95% confidence interval: 0.61-0.90; P = 0.003).
This study demonstrates that hospital quality score based on lymph node count can be used to identify underperforming hospitals.
调查评估癌症手术质量的方法,并根据这些质量指标对医院进行基准测试,可以提高美国的癌症治疗水平。我们试图确定淋巴结计数作为质量指标的效用。
我们对加利福尼亚癌症登记处数据库(2004-2011 年)与州卫生规划和发展办公室住院数据库进行了回顾性分析。纳入接受新辅助治疗和切除术的局部晚期直肠腺癌患者。医院质量评分定义为特定医院的患者中,至少有 9 个淋巴结进行充分检查的比例。高质量评分的医院是指在≥25%的手术中获取 9 个或更多淋巴结的医院。使用多变量 Cox 比例风险(标准和共享脆弱性)模型,在调整年龄、医院容量、种族、性别、保险、合并症、T 期、新辅助治疗反应、辅助化疗和教学医院地位等协变量后,确定总生存率的差异。
共有 2704 例患者在 228 家医院接受治疗(低评分医院=85 家,高评分医院=143 家)。患者和疾病特征在两组之间相似。社会经济状况和医院特征与评分状态密切相关。高评分医院具有更高的括约肌保留率(P=0.004)、更低的并发症发生率(P=0.021)和死亡率降低的趋势(P=0.079)。高评分医院的治疗独立预测总生存率(风险比:0.74;95%置信区间:0.61-0.90;P=0.003)。
本研究表明,基于淋巴结计数的医院质量评分可用于识别表现不佳的医院。